Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04320173 · ClinicalTrials.gov registry record · Phase 1
Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Lidocaine Patch 5% and Lidocaine Medicated Plaster 5% in Healthy, Adult, Human Subjects
A Phase 1 study, sponsored by Scilex Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT04320173 is a Phase 1 study that has completed, run by Scilex Pharmaceuticals. The registered enrollment target is 47 participants.
The verdict
NCT04320173, a Phase 1 study, has completed, sponsored by Scilex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The primary objective of this study was to evaluate the adhesion performance of ZTlido® (lidocaine topical system) 1.8% compared to adhesion performance for Lidoderm® (lidocaine patch 5%) and Versatis® (lidocaine medicated plaster 5%).
Interventions
- DRUG Lidocaine patch 1.8%
- DRUG Lidocaine patch 5%
- DRUG Lidocaine medicated plaster 5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-02-14 |
| Est. Completion | 2017-03-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04320173
The ClinicalTrials.gov registry entry for NCT04320173 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scilex Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lidocaine patch 1.8% is the first listed.
NCT04320173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04320173 about?
NCT04320173 is a clinical study titled "Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Lidocaine Patch 5% and Lidocaine Medicated Plaster 5% in Healthy, Adult, Human Subjects". The primary objective of this study was to evaluate the adhesion performance of ZTlido® (lidocaine topical system) 1.8% compared to adhesion performance for Lidoderm® (lidocaine patch 5%) and Versatis® (lidocaine medicated plaster 5%).
What is the current status of trial NCT04320173?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2017-02-14. Estimated completion is 2017-03-22.
What interventions are being tested in trial NCT04320173?
The interventions under investigation include: Lidocaine patch 1.8% (DRUG), Lidocaine patch 5% (DRUG), Lidocaine medicated plaster 5% (DRUG).
Who is sponsoring clinical trial NCT04320173?
This trial is sponsored by Scilex Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.